Keywords: Boehringer Ingelheim, Flibanserin, Female sexual arousel, Research

Boehringer Ingelheim’s “female Viagra” flibanserin fails to meet efficacy endpoints, say US FDA reviewers

Article | 17 June 2010

Print This

According to documents released yesterday, ahead of a US Food and Drug Administration advisory review panel meeting on Friday (June 18), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in